Amygdala Insula Retraining in the Management of Long COVID Symptoms

Long COVID Clinical Trial

Official title:

Amygdala Insula Retraining in the Management of Long COVID Symptoms

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05851846
• Other study ID #: 1677529-1
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 15, 2023
• Est. completion date: June 15, 2024

Study information

• Verified date: May 2023
• Source: Miami VA Healthcare System
• Contact: Leonardo Tamariz, MD
• Phone: 305-575-7000
• Email: leonardo.tamariz[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the study is to compare a mind body intervention against usual care in patients with fatigue with long COVID.

Our research questions include

1. Is the mind body intervention additive to usual care in long COVID

2. Can the mind body intervention change laboratory markers, heart rate variability and dysautonomia.

Description:

More than 30 percent of the over 70 million individuals in the United States who experienced an acute COVID-19 infection as a result of severe acute respiratory coronavirus-2 (SARS-CoV2), have variety of lingering and disabling symptoms that last beyond the acute phase of the illness. [1]This condition is referred to as Post-Acute Sequalae SARS-CoV-2 infection (PASC). Symptoms (including fatigue, post-exertional malaise (PEM), cardiovascular dysfunction, respiratory distress, gastrointestinal disturbances, and dermatologic issues) associated with PASC vary and can affect multiple organ systems. These symptoms are similar to, in extent and degree, to other neuro-immune conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). PASC, as with ME/CFS, is likely to pose a significant impact on the healthcare system and patient's quality of life. An unmet need exists as the susceptibility and pathogenesis of PASC remains yet to be fully elucidated. Emerging evidence suggests that existing interventions widely used for other neuro-immune conditions may prove equally effective in the treatment of PASC. Repurposing of drugs or identification of new drugs will take time. Still, there is growing evidence of the mind-body connection in modulating the autonomic, central and peripheral nervous systems as well as the immune system and the gastrointestinal tract. Recent studies have documented that holistic strategies such as mindfulness, meditation, and amygdala and insula retraining (AIR) have an objective measurable effect on heart rate variability, fatigue, pain, quality of life, depression, anxiety, and gastrointestinal symptoms. The mechanisms proposed include activation of vagus nerve, balancing the autonomic nervous system, reducing stress, and improving immune function. AIR is based on the principle that viral, bacterial, or environmental insults can sensitize the amygdala, which becomes hypervigilant and unleashes a cascade of hormonal responses that perpetuate a state of neuroinflammation and dysautonomia. AIR de-sensitizes the amygdala, breaking vicious cycles and reducing the maladaptive release of hormones and cytokines. Our clinical group has already recommended the use of AIR with great anecdotical response in clinical practice. This strategy is readily available and has no contraindications or risks. We aim to conduct a pilot study of AIR to generate preliminary data for a larger, federally funded trial. Our specific aims are:

1. Identify 130 subjects within the Miami Veteran's Administration (VA) Medical Center who experienced an acute COVID-19 infection and continue to experience persistent moderate fatigue (using standard questionnaires). Subjects will be randomized to either 1. AIR + standard of care or 2. Standard of care/wait list. Individuals in this latter arm will be waitlisted to receive the AIR intervention after they complete the study.

2. Collect standard questionnaires recommended by the Veterans Affairs Healthcare System at baseline, three, and six months to capture levels of fatigue (primary outcome), post exertional malaise (PEM), brain fog, pain, and other symptoms and compare changes over time across the two study arms.

3. Collect objective biometric data in a sample of patients at baseline and at three and six months to explore potential mediating mechanisms: heart rate variability, heart rate and blood pressure sitting and standing, inflammatory markers (c-reactive protein, cortisol, and Epstein Barr viral reactivation. The laboratory tests will not be collected for research purposes as they are collected for clinical purposes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 130
• Est. completion date: June 15, 2024
• Est. primary completion date: May 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The inclusion criteria will be:

1. Fulfill the definition of PASC

2. Be a patient in the Miami VA post COVID clinic

3. Have access to a computer or phone

4. Report moderate fatigue as defined by the clinically obtained surveys in the post COVID clinic. The rationale for this inclusion criteria is that 85% of our post COVID patient report fatigue and fatigue is a target outcome can be followed.

5. A probable or confirmed diagnosis of acute COVID-19 infection as per WHO guidelines.

6. Have no evidence of cardiac or pulmonary end organ damage, as per WHO definition. We will define not having end organ damage as a normal ejection fraction on echocardiogram and no pulmonary infiltrates on a non-contrast computed tomography (CT) of the chest during the work-up of the long COVID clinic.

Exclusion Criteria:

• There will be no exclusion criteria

Related Conditions & MeSH terms

• Long COVID

Intervention

Behavioral:
• Amygdala insula retraining
Mind body intrevention

Locations

Country	Name	City	State
United States	Institute for Neuroimmune Medcince	Fort Lauderdale	Florida
United States	Institute for Neuroinmune medicine	Miami	Florida
United States	Miami VAHS	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Miami VA Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Modified Yorkshire COVID-19 scale	Long COVID symptom scale	3 months
Secondary	Heart rate variability	SSDN	3 months
Secondary	COMPASS-31	Dysautonomia scale	3 months